Why the study?
Does single-agent therapy with atenolol or penbutolol control blood pressure in patients with moderate hypertension previously on combination therapy?
Does single-agent therapy with atenolol or penbutolol control blood pressure in patients with moderate hypertension previously on combination therapy?
Single-agent therapy with once-daily atenolol or penbutolol can effectively control blood pressure in patients with moderate hypertension previously treated with combination therapy.
Supports de-escalation to beta-blocker monotherapy in moderate hypertension; extends evidence to patients previously requiring combinations.
Antihypertensive therapy was stopped in twenty-one patients with moderate hypertension. Almost all of them had been on combination therapy, usually propranolol or metoprolol with chlorthalidone, for more than a year. After a placebo 'wash-out' period of 4 weeks patients were randomly allocated in a controlled trial to a fixed daily dose of either 100 mg atenolol or 40 mg penbutolol for 6 weeks. Single-agent therapy at these doses successfully controlled the blood pressure in nineteen of the twenty-one patients, including six previously inadequately controlled on a combination. Although no conclusions can be drawn about the long-term benefits, in the patient population under study either penbutolol or atenolol given at a standard dose should provide good initial blood pressure control in most patients with mild to moderate hypertension.
No takes yet. Share an insight, caveat, or question.
Houtzagers et al. (1982) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: